BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

463 related articles for article (PubMed ID: 22484425)

  • 1. MYCN and ALKF1174L are sufficient to drive neuroblastoma development from neural crest progenitor cells.
    Schulte JH; Lindner S; Bohrer A; Maurer J; De Preter K; Lefever S; Heukamp L; Schulte S; Molenaar J; Versteeg R; Thor T; Künkele A; Vandesompele J; Speleman F; Schorle H; Eggert A; Schramm A
    Oncogene; 2013 Feb; 32(8):1059-65. PubMed ID: 22484425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells.
    Schönherr C; Ruuth K; Kamaraj S; Wang CL; Yang HL; Combaret V; Djos A; Martinsson T; Christensen JG; Palmer RH; Hallberg B
    Oncogene; 2012 Dec; 31(50):5193-200. PubMed ID: 22286764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Wild-type ALK and activating ALK-R1275Q and ALK-F1174L mutations upregulate Myc and initiate tumor formation in murine neural crest progenitor cells.
    Montavon G; Jauquier N; Coulon A; Peuchmaur M; Flahaut M; Bourloud KB; Yan P; Delattre O; Sommer L; Joseph JM; Janoueix-Lerosey I; Gross N; Mühlethaler-Mottet A
    Oncotarget; 2014 Jun; 5(12):4452-66. PubMed ID: 24947326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alternative NHEJ pathway proteins as components of MYCN oncogenic activity in human neural crest stem cell differentiation: implications for neuroblastoma initiation.
    Newman EA; Chukkapalli S; Bashllari D; Thomas TT; Van Noord RA; Lawlor ER; Hoenerhoff MJ; Opipari AW; Opipari VP
    Cell Death Dis; 2017 Dec; 8(12):3208. PubMed ID: 29238067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bmi-1 is essential for the tumorigenicity of neuroblastoma cells.
    Cui H; Hu B; Li T; Ma J; Alam G; Gunning WT; Ding HF
    Am J Pathol; 2007 Apr; 170(4):1370-8. PubMed ID: 17392175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MYCN induces neuroblastoma in primary neural crest cells.
    Olsen RR; Otero JH; García-López J; Wallace K; Finkelstein D; Rehg JE; Yin Z; Wang YD; Freeman KW
    Oncogene; 2017 Aug; 36(35):5075-5082. PubMed ID: 28459463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma.
    Berry T; Luther W; Bhatnagar N; Jamin Y; Poon E; Sanda T; Pei D; Sharma B; Vetharoy WR; Hallsworth A; Ahmad Z; Barker K; Moreau L; Webber H; Wang W; Liu Q; Perez-Atayde A; Rodig S; Cheung NK; Raynaud F; Hallberg B; Robinson SP; Gray NS; Pearson AD; Eccles SA; Chesler L; George RE
    Cancer Cell; 2012 Jul; 22(1):117-30. PubMed ID: 22789543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ALK is a MYCN target gene and regulates cell migration and invasion in neuroblastoma.
    Hasan MK; Nafady A; Takatori A; Kishida S; Ohira M; Suenaga Y; Hossain S; Akter J; Ogura A; Nakamura Y; Kadomatsu K; Nakagawara A
    Sci Rep; 2013 Dec; 3():3450. PubMed ID: 24356251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification.
    De Brouwer S; De Preter K; Kumps C; Zabrocki P; Porcu M; Westerhout EM; Lakeman A; Vandesompele J; Hoebeeck J; Van Maerken T; De Paepe A; Laureys G; Schulte JH; Schramm A; Van Den Broecke C; Vermeulen J; Van Roy N; Beiske K; Renard M; Noguera R; Delattre O; Janoueix-Lerosey I; Kogner P; Martinsson T; Nakagawara A; Ohira M; Caron H; Eggert A; Cools J; Versteeg R; Speleman F
    Clin Cancer Res; 2010 Sep; 16(17):4353-62. PubMed ID: 20719933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proliferation and Survival of Embryonic Sympathetic Neuroblasts by MYCN and Activated ALK Signaling.
    Kramer M; Ribeiro D; Arsenian-Henriksson M; Deller T; Rohrer H
    J Neurosci; 2016 Oct; 36(40):10425-10439. PubMed ID: 27707976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MYCN promotes the expansion of Phox2B-positive neuronal progenitors to drive neuroblastoma development.
    Alam G; Cui H; Shi H; Yang L; Ding J; Mao L; Maltese WA; Ding HF
    Am J Pathol; 2009 Aug; 175(2):856-66. PubMed ID: 19608868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic regulation of the neuroblastoma genes, Arid3b and Mycn.
    Kobayashi K; Jakt LM; Nishikawa SI
    Oncogene; 2013 May; 32(21):2640-8. PubMed ID: 22751132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High levels of HIF-2alpha highlight an immature neural crest-like neuroblastoma cell cohort located in a perivascular niche.
    Pietras A; Gisselsson D; Ora I; Noguera R; Beckman S; Navarro S; Påhlman S
    J Pathol; 2008 Mar; 214(4):482-8. PubMed ID: 18189331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma.
    Moore NF; Azarova AM; Bhatnagar N; Ross KN; Drake LE; Frumm S; Liu QS; Christie AL; Sanda T; Chesler L; Kung AL; Gray NS; Stegmaier K; George RE
    Oncotarget; 2014 Sep; 5(18):8737-49. PubMed ID: 25228590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activated ALK collaborates with MYCN in neuroblastoma pathogenesis.
    Zhu S; Lee JS; Guo F; Shin J; Perez-Atayde AR; Kutok JL; Rodig SJ; Neuberg DS; Helman D; Feng H; Stewart RA; Wang W; George RE; Kanki JP; Look AT
    Cancer Cell; 2012 Mar; 21(3):362-73. PubMed ID: 22439933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ALK pERKs up MYCN in neuroblastoma.
    Lindner S; Henssen A; Astrahantseff K; Schulte JH
    Sci Signal; 2014 Oct; 7(349):pe27. PubMed ID: 25351246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A genome-wide search for promoters that respond to increased MYCN reveals both new oncogenic and tumor suppressor microRNAs associated with aggressive neuroblastoma.
    Shohet JM; Ghosh R; Coarfa C; Ludwig A; Benham AL; Chen Z; Patterson DM; Barbieri E; Mestdagh P; Sikorski DN; Milosavljevic A; Kim ES; Gunaratne PH
    Cancer Res; 2011 Jun; 71(11):3841-51. PubMed ID: 21498633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional interplay between MYCN, NCYM, and OCT4 promotes aggressiveness of human neuroblastomas.
    Kaneko Y; Suenaga Y; Islam SM; Matsumoto D; Nakamura Y; Ohira M; Yokoi S; Nakagawara A
    Cancer Sci; 2015 Jul; 106(7):840-7. PubMed ID: 25880909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MYCN and MYC regulate tumor proliferation and tumorigenesis directly through BMI1 in human neuroblastomas.
    Huang R; Cheung NK; Vider J; Cheung IY; Gerald WL; Tickoo SK; Holland EC; Blasberg RG
    FASEB J; 2011 Dec; 25(12):4138-49. PubMed ID: 21856782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct effects of Bmi1 on p53 protein stability inactivates oncoprotein stress responses in embryonal cancer precursor cells at tumor initiation.
    Calao M; Sekyere EO; Cui HJ; Cheung BB; Thomas WD; Keating J; Chen JB; Raif A; Jankowski K; Davies NP; Bekkum MV; Chen B; Tan O; Ellis T; Norris MD; Haber M; Kim ES; Shohet JM; Trahair TN; Liu T; Wainwright BJ; Ding HF; Marshall GM
    Oncogene; 2013 Aug; 32(31):3616-26. PubMed ID: 22907436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.